Korean J Gastroenterol.  2017 May;69(5):328-331. 10.4166/kjg.2017.69.5.328.

Which of the Direct Oral Anticoagulants Is the Safest?: Based on Gastrointestinal Bleeding

• Jung K
• Park MI

• KMID: 2383394
• DOI: http://doi.org/10.4166/kjg.2017.69.5.328

Abstract

No abstract available.

MeSH Terms

Anticoagulants*
Hemorrhage*
Anticoagulants

Reference

1. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37:2893–2962.

2. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383:955–962.

3. Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015; 350:h1857.

4. Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology. 2017; 152:1014–1022.e1.

5. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146:857–867.

6. Harder S, Thürmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet. 1996; 30:416–444.

7. Bendel SD, Bona R, Baker WL. Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. Adv Ther. 2011; 28:460–472.

8. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2012; 26:27–32.

9. Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 2011; 31:478–492.

10. Mendell J, Zahir H, Matsushima N, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013; 13:331–342.

11. Reiffel JA, Weitz JI, Reilly P, et al. NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: a cardiac safety research consortium think tank. Am Heart J. 2016; 177:74–86.

12. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139–1151.

13. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883–891.

14. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981–992.

15. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369:2093–2104.

16. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2011; 4:14–21.

17. Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial ribrillation. Chest. 2016; 150:1302–1312.

18. Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016; 5:pii: e003725.

19. Kwon CH, Kim M, Kim J, Nam GB, Choi KJ, Kim YH. Real-world comparison of non-vitamin K antagonist oral anticoagulants and warfarin in Asian octogenarian patients with atrial fibrillation. J Geriatr Cardiol. 2016; 13:566–572.

20. Lee KH, Park HW, Cho JG, et al. Comparison of non-vitamin K antagonist oral anticoagulants and warfarin on clinical outcomes in atrial fibrillation patients with renal dysfunction. Europace. 2015; 17:Suppl 2. ii69–ii75.

21. Park CS, Choi EK, Kim HM, Lee SR, Cha MJ, Oh S. Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants. Heart Rhythm. 2017; 14:501–507.

22. Seong CS, Gwag HB, Hwang JK, et al. The persistence of non-vitamin K antagonist oral anticoagulants in Korean patients with non-valvular atrial fibrillation. Int J Arrhythm. 2016; 17:190–199.

23. Desai J, Kolb JM, Weitz JI, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thromb Haemost. 2013; 110:205–212.